
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4797501/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Colonic Lactulose Fermentation Has No Impact on Glucagon-like Peptide-1 and Peptide-YY Secretion in Healthy Young Men. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 77-87.	3.6	6
2	Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pumpâ€ŧreated type 1 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 212-220.	4.4	4
3	Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes: A post-hoc analysis of a randomized clinical trial. Free Radical Biology and Medicine, 2022, 178, 18-25.	2.9	1
4	GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment. Pharmacological Research, 2022, 176, 106058.	7.1	13
5	The Effect of Bariatric Surgery on Healthcare Costs and Labor Market Attachment. Obesity Surgery, 2022, 32, 998-1004.	2.1	3
6	Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Rouxâ€en‥ gastric bypass. Physiological Reports, 2022, 10, e15157.	1.7	3
7	Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial. Diabetologia, 2022, 65, 506-517.	6.3	37
8	Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. European Journal of Endocrinology, 2022, 186, 687-700.	3.7	12
9	Long-term outcomes of dietary carbohydrate restriction for HbA1c reduction in type 2 diabetes mellitus are needed. Reply to Kang J and Ma E [letter]. Diabetologia, 2022, , 1.	6.3	0
10	On measurements of glucagon secretion in healthy, obese, and Roux-en-Y gastric bypass operated individuals using sandwich ELISA. Scandinavian Journal of Clinical and Laboratory Investigation, 2022, 82, 75-83.	1.2	7
11	Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial. Human Reproduction, 2022, 37, 1414-1422.	0.9	34
12	Early effects of Roux-en-Y gastric bypass on dietary fatty acid absorption and metabolism in people with obesity and normal glucose tolerance. International Journal of Obesity, 2022, 46, 1359-1365.	3.4	0
13	Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy. Frontiers in Nutrition, 2022, 9, 889710.	3.7	4
14	Weight-loss induced by carbohydrate restriction does not negatively affect health-related quality of life and cognition in people with type 2 diabetes: A randomised controlled trial. Clinical Nutrition, 2022, , .	5.0	5
15	Influence of NAFLD and bariatric surgery on hepatic and adipose tissue mitochondrial biogenesis and respiration. Nature Communications, 2022, 13, .	12.8	14
16	Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 2017-2026.	4.4	9
17	Switching between GLPâ€1 receptor agonists in clinical practice: Expert consensus and practical guidance. International Journal of Clinical Practice, 2021, 75, e13731.	1.7	22
18	Impact of prolonged fasting on insulin secretion, insulin action, and hepatic versus whole body insulin secretion disposition indices in healthy young males. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E281-E290.	3.5	13

#	Article	IF	CITATIONS
19	Effects of carbohydrate restriction on postprandial glucose metabolism, β -cell function, gut hormone secretion, and satiety in patients with Type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E7-E18.	3.5	17
20	Effects of Roux-en-Y gastric bypass on circulating follistatin, activin A, and peripheral ActRIIB signaling in humans with obesity and type 2 diabetes. International Journal of Obesity, 2021, 45, 316-325.	3.4	3
21	The Renal Extraction and the Natriuretic Action of GLP-1 in Humans Depend on Interaction With the GLP-1 Receptor. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e11-e19.	3.6	12
22	What is Diabetes Remission?. Diabetes Therapy, 2021, 12, 641-646.	2.5	6
23	Comparable <scp>COVID</scp> â€19 outcomes with current use of <scp>GLP</scp> â€1 receptor agonists, <scp>DPP</scp> â€4 inhibitors or <scp>SGLT</scp> â€2 inhibitors among patients with diabetes who tested positive for <scp>SARSâ€CoV</scp> â€2. Diabetes, Obesity and Metabolism, 2021, 23, 1397-1401.	4.4	53
24	Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes. European Journal of Case Reports in Internal Medicine, 2021, 8, 002352.	0.4	0
25	Follistatin secretion is enhanced by protein, but not glucose or fat ingestion, in obese persons independently of previous gastric bypass surgery. American Journal of Physiology - Renal Physiology, 2021, 320, G753-G758.	3.4	1
26	Effects of a Self-Prepared Carbohydrate-Reduced High-Protein Diet on Cardiovascular Disease Risk Markers in Patients with Type 2 Diabetes. Nutrients, 2021, 13, 1694.	4.1	6
27	Weight Loss, Improved Body Composition and Fat Distribution by Tesomet in Acquired Hypothalamic Obesity. Journal of the Endocrine Society, 2021, 5, A64-A65.	0.2	4
28	Genetic markers of abdominal obesity and weight loss after gastric bypass surgery. PLoS ONE, 2021, 16, e0252525.	2.5	3
29	Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass. Frontiers in Endocrinology, 2021, 12, 681116.	3.5	7
30	Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine, 2021, 384, 1719-1730.	27.0	171
31	Body weight and metabolic risk factors in patients with type 2 diabetes on a self-selected high-protein low-carbohydrate diet. European Journal of Nutrition, 2021, 60, 4473-4482.	3.9	5
32	The role of GLP-1 in postprandial glucose metabolism after bariatric surgery: a narrative review of human GLP-1 receptor antagonist studies. Surgery for Obesity and Related Diseases, 2021, 17, 1383-1391.	1.2	19
33	Dulaglutide for erectile dysfunction in type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2021, 9, 472-473.	11.4	1
34	Neurotensin secretion after Rouxâ€en‥ gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty. Neurogastroenterology and Motility, 2021, , e14210.	3.0	2
35	Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies. Journal of Clinical Medicine, 2021, 10, 3783.	2.4	21
36	Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the <scp>ADJUNCT ONE</scp> and <scp>ADJUNCT TWO</scp> randomized controlled trials. Diabetes, Obesity and Metabolism, 2021, 23, 2752-2762.	4.4	16

#	Article	IF	CITATIONS
37	Plasma GDF15 levels are similar between subjects after bariatric surgery and matched controls and are unaffected by meals. American Journal of Physiology - Endocrinology and Metabolism, 2021, 321, E443-E452.	3.5	5
38	Metabolic improvement after gastric bypass correlates with changes in IGF-regulatory proteins stanniocalcin-2 and IGFBP-4. Metabolism: Clinical and Experimental, 2021, 124, 154886.	3.4	8
39	Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study. Bone, 2021, 152, 116065.	2.9	8
40	Fractionated free fatty acids and their relation to diabetes status after Rouxâ€en‥ gastric bypass: A cohort study. Physiological Reports, 2021, 9, e14708.	1.7	1
41	Intestinal sensing and handling of dietary lipids in gastric bypass–operated patients and matched controls. American Journal of Clinical Nutrition, 2020, 111, 28-41.	4.7	7
42	Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass. Journal of Bone and Mineral Metabolism, 2020, 38, 117-125.	2.7	7
43	Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulinâ€pumpâ€treated patients with type 1 diabetes: The Lira Pump trial—a randomized, doubleâ€blinded, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 492-500.	4.4	29
44	Impact of baseline characteristics and betaâ€cell function on the efficacy and safety of subcutaneous onceâ€weekly semaglutide: A patientâ€level, pooled analysis of the SUSTAIN 1â€5 trials. Diabetes, Obesity and Metabolism, 2020, 22, 303-314.	4.4	19
45	Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial. Cardiovascular Diabetology, 2020, 19, 150.	6.8	11
46	Prediction of carotid intima-media thickness and its relation to cardiovascular events in persons with type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107681.	2.3	1
47	The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study. Clinical Nutrition ESPEN, 2020, 39, 46-52.	1.2	8
48	Increased oral sodium chloride intake in humans amplifies selectively postprandial GLPâ€1 but not GIP, CCK, and gastrin in plasma. Physiological Reports, 2020, 8, e14519.	1.7	6
49	59 - Greater Reductions in HbA1c and Body Weight With Once-Weekly Semaglutide Vs Comparators Across Baseline BMI Subgroups: Posthoc Analysis of SUSTAIN 1–5 and 7–10. Canadian Journal of Diabetes, 2020, 44, S25-S26.	0.8	0
50	Mechanisms Underlying Absent Training-Induced Improvement in Insulin Action in Lean, Hyperandrogenic Women With Polycystic Ovary Syndrome. Diabetes, 2020, 69, 2267-2280.	0.6	13
51	Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis. Hepatology Communications, 2020, 4, 1610-1623.	4.3	22
52	Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomy. International Journal of Obesity, 2020, 44, 1872-1883.	3.4	13
53	Effects of a highly controlled carbohydrate-reduced high-protein diet on markers of oxidatively generated nucleic acid modifications and inflammation in weight stable participants with type 2 diabetes; a randomized controlled trial. Scandinavian Journal of Clinical and Laboratory Investigation. 2020. 80. 401-407.	1.2	10
54	Effect of Metformin vs. Placebo in Combination with Insulin Analogues on Bone Markers P1NP and CTX in Patients with Type 2 Diabetes Mellitus. Calcified Tissue International, 2020, 107, 160-169.	3.1	7

#	Article	IF	CITATIONS
55	No effects of a 6â€week intervention with a glucagonâ€like peptideâ€1 receptor agonist on pancreatic volume and oedema in obese men without diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1837-1846.	4.4	4
56	Metformin monotherapy for adults with type 2 diabetes mellitus. The Cochrane Library, 2020, 2020, CD012906.	2.8	21
57	The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery. American Journal of Physiology - Endocrinology and Metabolism, 2020, 318, E956-E964.	3.5	13
58	Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 313-324.	11.4	39
59	Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine. International Journal of Obesity, 2020, 44, 1859-1871.	3.4	25
60	Responses of gut and pancreatic hormones, bile acids, and fibroblast growth factor-21 differ to glucose, protein, and fat ingestion after gastric bypass surgery. American Journal of Physiology - Renal Physiology, 2020, 318, G661-G672.	3.4	27
61	The Antiresorptive Effect of GIP, But Not GLP-2, Is Preserved in Patients With Hypoparathyroidism—A Randomized Crossover Study. Journal of Bone and Mineral Research, 2020, 36, 1448-1458.	2.8	17
62	GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report. Cell Reports Medicine, 2020, 1, 100006.	6.5	22
63	Reduction of oxidative stress on DNA and RNA in obese patients after Roux-en-Y gastric bypass surgery—An observational cohort study of changes in urinary markers. PLoS ONE, 2020, 15, e0243918.	2.5	10
64	Title is missing!. , 2020, 15, e0243918.		0
65	Title is missing!. , 2020, 15, e0243918.		0
66	Title is missing!. , 2020, 15, e0243918.		0
67	Title is missing!. , 2020, 15, e0243918.		0
68	Title is missing!. , 2020, 15, e0243918.		0
69	Title is missing!. , 2020, 15, e0243918.		Ο
70	Mechanisms involved in follistatinâ€induced hypertrophy and increased insulin action in skeletal muscle. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 1241-1257.	7.3	47
71	Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. Atherosclerosis, 2019, 288, 60-66.	0.8	43
72	A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial. Diabetologia, 2019, 62, 2066-2078.	6.3	98

#	Article	IF	CITATIONS
73	Sustained Improvements in Glucose Metabolism Late After Roux-En-Y Gastric Bypass Surgery in Patients with and Without Preoperative Diabetes. Scientific Reports, 2019, 9, 15154.	3.3	6
74	Phosphatidylcholine and its relation to apolipoproteins A-1 and B changes after Roux-en-Y gastric bypass: a cohort study. Lipids in Health and Disease, 2019, 18, 169.	3.0	5
75	Augmented GLP-1 Secretion as Seen After Gastric Bypass May Be Obtained by Delaying Carbohydrate Digestion. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3233-3244.	3.6	15
76	Pros and cons of Roux en-Y gastric bypass surgery in obese patients with type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2019, 14, 243-257.	2.4	5
77	Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease. Diabetology and Metabolic Syndrome, 2019, 11, 42.	2.7	10
78	GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men. Bone, 2019, 125, 178-185.	2.9	45
79	Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. Frontiers in Endocrinology, 2019, 10, 242.	3.5	5
80	Extracellular Fluid Volume Expansion Uncovers a Natriuretic Action of GLP-1: A Functional GLP-1–Renal Axis in Man. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2509-2519.	3.6	29
81	Genetic Determinants of Weight Loss After Bariatric Surgery. Obesity Surgery, 2019, 29, 2554-2561.	2.1	17
82	Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients. Expert Review of Cardiovascular Therapy, 2019, 17, 377-387.	1.5	8
83	Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. Diabetes, Obesity and Metabolism, 2019, 21, 2012-2016.	4.4	14
84	Postprandial Nutrient Handling and Gastrointestinal Hormone Secretion After Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. Gastroenterology, 2019, 156, 1627-1641.e1.	1.3	99
85	Bariatric surgery—which procedure is the optimal choice?. Lancet, The, 2019, 393, 1263-1264.	13.7	10
86	Assessment of Islet Alpha- and Beta-Cell Function. , 2019, , 37-74.		1
87	Molecular Mechanisms in Skeletal Muscle Underlying Insulin Resistance in Women Who Are Lean With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1841-1854.	3.6	50
88	The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults. IJC Heart and Vasculature, 2019, 22, 139-144.	1.1	5
89	Effect of bariatric surgery on plasma GDF15 in humans. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E615-E621.	3.5	25
90	Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet. BMJ Open, 2019, 9, e031431.	1.9	11

#	Article	IF	CITATIONS
91	Metabolic Health in Severely Obese Subjects: A Descriptive Study. Metabolic Syndrome and Related Disorders, 2019, 17, 115-119.	1.3	3
92	Mechanisms of action of a carbohydrate-reduced, high-protein diet in reducing the risk of postprandial hypoglycemia after Roux-en-Y gastric bypass surgery. American Journal of Clinical Nutrition, 2019, 110, 296-304.	4.7	22
93	Treatment with GLP-1 Receptor Agonists. Endocrinology, 2018, , 1-45.	0.1	3
94	Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss. Surgery for Obesity and Related Diseases, 2018, 14, 708-714.	1.2	144
95	A carbohydrate-reduced high-protein diet acutely decreases postprandial and diurnal glucose excursions in type 2 diabetes patients. British Journal of Nutrition, 2018, 119, 910-917.	2.3	39
96	Systems Signatures Reveal Unique Remission-path of Type 2 Diabetes Following Roux-en-Y Gastric Bypass Surgery. EBioMedicine, 2018, 28, 234-240.	6.1	5
97	Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study. Diabetes Care, 2018, 41, 797-806.	8.6	10
98	Metformin monotherapy for adults with type 2 diabetes mellitus. The Cochrane Library, 2018, , .	2.8	6
99	Relationship between Optimum Miniâ€doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes – A Simulation Study. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 322-330.	2.5	4
100	Overnight glucose control in people with type 1 diabetes. Biomedical Signal Processing and Control, 2018, 39, 503-512.	5.7	40
101	The acute effects of dietary carbohydrate reduction on postprandial responses of non-esterified fatty acids and triglycerides: a randomized trial. Lipids in Health and Disease, 2018, 17, 295.	3.0	9
102	Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scandinavian Journal of Gastroenterology, 2018, 53, 1429-1432.	1.5	17
103	Plasma Proteome Profiling Reveals Dynamics of Inflammatory and Lipid Homeostasis Markers after Roux-En-Y Gastric Bypass Surgery. Cell Systems, 2018, 7, 601-612.e3.	6.2	80
104	Hepatic Insulin Clearance in Regulation of Systemic Insulin Concentrations—Role of Carbohydrate and Energy Availability. Diabetes, 2018, 67, 2129-2136.	0.6	74
105	Preoperative High-Dose Methylprednisolone and Glycemic Control Early After Total Hip and Knee Arthroplasty. Anesthesia and Analgesia, 2018, 127, 906-913.	2.2	15
106	Treatment with GLP-1 Receptor Agonists. Endocrinology, 2018, , 571-615.	0.1	1
107	Acute Effects of Dietary Carbohydrate Restriction on Glycemia, Lipemia and Appetite Regulating Hormones in Normal-Weight to Obese Subjects. Nutrients, 2018, 10, 1285.	4.1	12
108	Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. Cell Metabolism, 2018, 28, 23-32.e3.	16.2	88

#	Article	IF	CITATIONS
109	Changes in Serum Sphingomyelin After Roux-en-Y Gastric Bypass Surgery Are Related to Diabetes Status. Frontiers in Endocrinology, 2018, 9, 172.	3.5	10
110	Non-insulin pharmacological therapies for treating type 1 diabetes. Expert Opinion on Pharmacotherapy, 2018, 19, 947-960.	1.8	25
111	After Roux-en-Y Gastric Bypass, Enterohepatic Bile Circulation Is Altered and Bile Acid Retention Increased while Bile Acid Homeostasis Remains Normal after Sleeve Gastrectomy. Diabetes, 2018, 67, .	0.6	2
112	Liraglutide effects on betaâ€cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 850-857.	4.4	19
113	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet, The, 2017, 389, 1399-1409.	13.7	502
114	Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2017, 11, 1101-1111.	2.2	14
115	Variable reliability of surrogate measures of insulin sensitivity after Roux-en-Y gastric bypass. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2017, 312, R797-R805.	1.8	15
116	A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite. American Journal of Physiology - Endocrinology and Metabolism, 2017, 313, E284-E291.	3.5	13
117	Glycaemic control and weight loss with semaglutide in type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2017, 5, 315-317.	11.4	4
118	Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes. Expert Review of Clinical Pharmacology, 2017, 10, 621-632.	3.1	13
119	Effect of large weight reductions on measured and estimated kidney function. BMC Nephrology, 2017, 18, 52.	1.8	34
120	Chenodeoxycholic acid stimulates glucagonâ€like peptideâ€1 secretion in patients after Rouxâ€enâ€Y gastric bypass. Physiological Reports, 2017, 5, e13140.	1.7	32
121	Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease. Journal of Hypertension, 2017, 35, 1070-1078.	0.5	37
122	Shortâ€ŧerm effects of a low carbohydrate diet on glycaemic variables and cardiovascular risk markers in patients with type 1 diabetes: <scp>A</scp> randomized open″abel crossover trial. Diabetes, Obesity and Metabolism, 2017, 19, 1479-1484.	4.4	67
123	Emerging drugs for the treatment of obesity. Expert Opinion on Emerging Drugs, 2017, 22, 87-99.	2.4	29
124	Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 734-738.	4.4	16
125	S100A8/A9 (Calprotectin), Interleukin-6, and C-Reactive Protein in Obesity and Diabetes before and after Roux-en-Y Gastric Bypass Surgery. Obesity Facts, 2017, 10, 386-395.	3.4	17
126	Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. Journal of Diabetes and Its Complications, 2017, 31, 1164-1168.	2.3	6

#	Article	IF	CITATIONS
127	Instrumentalization of Eating Improves Weight Loss Maintenance in Obesity. Obesity Facts, 2017, 10, 633-647.	3.4	23
128	Circulating Clucagon 1-61 Regulates Blood Clucose by Increasing Insulin Secretion and Hepatic Glucose Production. Cell Reports, 2017, 21, 1452-1460.	6.4	28
129	Low-Carbohydrate Diet Impairs the Effect of Clucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study. Diabetes Care, 2017, 40, 132-135.	8.6	60
130	Comparative studies of insulin vs glucagonâ€like peptideâ€l receptor agonists in patients initiating injectable therapy. Diabetes, Obesity and Metabolism, 2017, 19, 153-155.	4.4	2
131	Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. Diabetes Care, 2017, 40, 117-124.	8.6	72
132	The impact of gastric bypass surgery on sex hormones and menstrual cycles in premenopausal women. Gynecological Endocrinology, 2017, 33, 160-163.	1.7	28
133	Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: <scp>A</scp> randomized, placeboâ€controlled, doubleâ€blind, parallelâ€group study. Diabetes, Obesity and Metabolism, 2017, 19, 773-782.	4.4	28
134	Semaglutide seems to be more effective the other GLP-1Ras. Annals of Translational Medicine, 2017, 5, 505-505.	1.7	31
135	Glucagonâ€like peptideâ€1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men. Physiological Reports, 2017, 5, e13073.	1.7	31
136	Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB. Diabetes, 2016, 65, 239-254.	0.6	41
137	Surgical or medical therapy for patients with obesity and T2DM?. Nature Reviews Endocrinology, 2016, 12, 500-502.	9.6	1
138	Retinal characteristics during 1Âyear of insulin pump therapy in type 1 diabetes: a prospective, controlled, observational study. Acta Ophthalmologica, 2016, 94, 540-547.	1.1	14
139	Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial. BMJ Open, 2016, 6, e008377.	1.9	11
140	Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. Genome Medicine, 2016, 8, 67.	8.2	260
141	Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus—the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial. BMJ Open, 2016, 6, e008376.	1.9	30
142	Proteomics reveals the effects of sustained weight loss on the human plasma proteome. Molecular Systems Biology, 2016, 12, 901.	7.2	188
143	Gastric bypass surgery reveals independency of obesity and diabetes melitus type 2. BMC Endocrine Disorders, 2016, 16, 59.	2.2	11
144	Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study. Cardiovascular Diabetology, 2016, 15, 105.	6.8	48

#	Article	IF	CITATIONS
145	Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surgery for Obesity and Related Diseases, 2016, 12, 1236-1242.	1.2	59
146	Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. American Journal of Physiology - Endocrinology and Metabolism, 2016, 310, E505-E514.	3.5	56
147	No Islet Cell Hyperfunction, but Altered Gut-Islet Regulation and Postprandial Hypoglycemia in Glucose-Tolerant Patients 3ÂYears After Gastric Bypass Surgery. Obesity Surgery, 2016, 26, 2263-2267.	2.1	20
148	Relationship Between Two Common Lipoprotein Lipase Variants and the Metabolic Syndrome and Its Individual Components. Metabolic Syndrome and Related Disorders, 2016, 14, 442-448.	1.3	3
149	Review of headâ€toâ€head comparisons of glucagonâ€like peptideâ€1 receptor agonists. Diabetes, Obesity and Metabolism, 2016, 18, 317-332.	4.4	211
150	Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels. Metabolomics, 2016, 12, 1.	3.0	0
151	Metformin and sulphonylurea (second- or third-generation) combination therapy for adults with type 2 diabetes mellitus. The Cochrane Library, 2016, , .	2.8	1
152	In vivo and in vitro degradation of peptide YY _{3–36} to inactive peptide YY _{3–34} in humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 310, R866-R874.	1.8	46
153	Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 221-232.	11.4	127
154	Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3–36. European Journal of Endocrinology, 2016, 174, 775-784.	3.7	72
155	Major rapid weight loss induces changes in cardiac repolarization. Journal of Electrocardiology, 2016, 49, 467-472.	0.9	12
156	Liraglutide for treating type 1 diabetes. Expert Opinion on Biological Therapy, 2016, 16, 579-590.	3.1	15
157	Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. Lancet Diabetes and Endocrinology,the, 2016, 4, 766-780.	11.4	74
158	Impact of postprandial glucose control on diabetes-related complications: How is the evidence evolving?. Journal of Diabetes and Its Complications, 2016, 30, 374-385.	2.3	54
159	Enhanced insulin signaling in human skeletal muscle and adipose tissue following gastric bypass surgery. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 309, R510-R524.	1.8	42
160	Postoperative Morbidity and Mortality in Type-2 Diabetics After Fast-Track Primary Total Hip and Knee Arthroplasty. Anesthesia and Analgesia, 2015, 120, 230-238.	2.2	62
161	Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetesa protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. BMJ Open, 2015, 5, e007791-e007791.	1.9	12
162	Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass. American Journal of Physiology - Endocrinology and Metabolism, 2015, 308, E535-E544.	3.5	62

#	Article	IF	CITATIONS
163	Changes in Hematology and Calcium Metabolism After Gastric Bypass Surgery—a 2-Year Follow-Up Study. Obesity Surgery, 2015, 25, 1647-1652.	2.1	24
164	Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance. Diabetologia, 2015, 58, 920-928.	6.3	27
165	Prenatal exposure to persistent organochlorine pollutants is associated with high insulin levels in 5-year-old girls. Environmental Research, 2015, 142, 407-413.	7.5	30
166	GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2909-2917.	3.6	116
167	Effects of Roux-en-Y gastric bypass on fasting and postprandial inflammation-related parameters in obese subjects with normal glucose tolerance and in obese subjects with type 2 diabetes. Diabetology and Metabolic Syndrome, 2015, 7, 12.	2.7	42
168	Improvements in Glucose Metabolism Early After Gastric Bypass Surgery Are Not Explained by Increases in Total Bile Acids and Fibroblast Growth Factor 19 Concentrations. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E396-E406.	3.6	89
169	Updates in weight loss surgery and gastrointestinal peptides. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 21-28.	2.3	24
170	The Impact of Nocturnal Hypoglycemia on Sleep in Subjects With Type 2 Diabetes. Diabetes Care, 2015, 38, 2151-2157.	8.6	15
171	Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study. Diabetes Care, 2015, 38, 2250-2257.	8.6	91
172	Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. American Journal of Clinical Nutrition, 2015, 102, 600-607.	4.7	50
173	Bariatric Surgery - Effects on Obesity and Related co-Morbidities. Current Diabetes Reviews, 2014, 10, 208-214.	1.3	48
174	Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol. BMJ Open, 2014, 4, e005942-e005942.	1.9	11
175	LY2605541A Preferential Hepato-Specific Insulin Analogue. Diabetes, 2014, 63, 390-392.	0.6	20
176	GLP-1 as a Mediator in the Remission of Type 2 Diabetes After Gastric Bypass and Sleeve Gastrectomy Surgery. Diabetes, 2014, 63, 3172-3174.	0.6	49
177	Early Enhancements of Hepatic and Later of Peripheral Insulin Sensitivity Combined With Increased Postprandial Insulin Secretion Contribute to Improved Glycemic Control After Roux-en-Y Gastric Bypass. Diabetes, 2014, 63, 1725-1737.	0.6	220
178	Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?. Diabetologia, 2014, 57, 1919-1926.	6.3	156
179	Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report. BMC Research Notes, 2014, 7, 326.	1.4	1
180	Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes and Endocrinology,the, 2014, 2, 152-164.	11.4	248

#	Article	IF	CITATIONS
181	Effects of gastric bypass surgery on glucose absorption and metabolism during a mixed meal in glucose-tolerant individuals. Diabetologia, 2013, 56, 2250-2254.	6.3	100
182	Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. Diabetologia, 2013, 56, 2679-2687.	6.3	82
183	CRP and suPAR are differently related to anthropometry and subclinical organ damage. International Journal of Cardiology, 2013, 167, 781-785.	1.7	99
184	Under-reporting of adverse effects of tesofensine. Lancet, The, 2013, 382, 127.	13.7	9
185	Reduction in cardiovascular risk factors and insulin dose, but no beta-cell regeneration 1 year after Roux-en-Y gastric bypass in an obese patient with type 1 diabetes: A case report. Obesity Research and Clinical Practice, 2013, 7, e269-e274.	1.8	18
186	Treatment of the Metabolic Syndrome by Bariatric Surgery. , 2013, , 191-219.		0
187	Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance. Diabetes, 2013, 62, 2088-2094.	0.6	75
188	Increased Hepatic Insulin Clearance After Roux-en-Y Gastric Bypass. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1066-E1071.	3.6	66
189	Soluble urokinase plasminogen activator receptor, <scp>C</scp> â€reactive protein and triglyceride are associated with heart rate variability in nonâ€diabetic Danes. European Journal of Clinical Investigation, 2013, 43, 457-468.	3.4	10
190	Model-Based Closed-Loop Glucose Control in Type 1 Diabetes: The DiaCon Experience. Journal of Diabetes Science and Technology, 2013, 7, 1255-1264.	2.2	30
191	Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved β-Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes. Diabetes, 2013, 62, 3044-3052.	0.6	262
192	Effects of Roux-en-Y Gastric Bypass on Fasting and Postprandial Levels of the Inflammatory Markers YKL-40 and MCP-1 in Patients with Type 2 Diabetes and Glucose Tolerant Subjects. Journal of Obesity, 2013, 2013, 1-10.	2.7	14
193	Genetic Variation in the Natriuretic Peptide System, Circulating Natriuretic Peptide Levels, and Blood Pressure: An Ambulatory Blood Pressure Study. American Journal of Hypertension, 2012, 25, 1095-1100.	2.0	11
194	Effects of Everyday Life Events on Glucose, Insulin, and Glucagon Dynamics in Continuous Subcutaneous Insulin Infusion–Treated Type 1 Diabetes: Collection of Clinical Data for Glucose Modeling. Diabetes Technology and Therapeutics, 2012, 14, 210-217.	4.4	17
195	Type 2 diabetes: which drug as add-on to metformin?. Lancet, The, 2012, 379, 2222-2223.	13.7	2
196	Adipose expression of adipocytokines in women with polycystic ovary syndrome. Fertility and Sterility, 2012, 98, 235-241.	1.0	59
197	Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No. European Journal of Internal Medicine, 2012, 23, 132-136.	2.2	15
198	The effect of a very low calorie diet on insulin sensitivity, beta cell function, insulin clearance, incretin hormone secretion, androgen levels and body composition in obese young women. Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 410-419.	1.2	42

#	Article	IF	CITATIONS
199	Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes. Diabetes Care, 2011, 34, S251-S257.	8.6	233
200	Skeletal muscle mitochondrial function in polycystic ovarian syndrome. European Journal of Endocrinology, 2011, 165, 631-637.	3.7	23
201	Pleiotropic Effects of GIP on Islet Function Involve Osteopontin. Diabetes, 2011, 60, 2424-2433.	0.6	83
202	Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function. Diabetes, 2011, 60, 1599-1607.	0.6	131
203	Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function. Diabetes Care, 2011, 34, 1463-1468.	8.6	143
204	Studies of the Association of Arg72Pro of Tumor Suppressor Protein p53 with Type 2 Diabetes in a Combined Analysis of 55,521 Europeans. PLoS ONE, 2011, 6, e15813.	2.5	49
205	Sustained lowâ€dose growth hormone therapy optimizes bioactive insulinâ€like growth factorâ€l level and may enhance CD4 Tâ€cell number in HIV infection. Journal of Medical Virology, 2010, 82, 197-205.	5.0	3
206	Postprandial Diabetic Glucose Tolerance Is Normalized by Gastric Bypass Feeding as Opposed to Gastric Feeding and Is Associated With Exaggerated GLP-1 Secretion. Diabetes Care, 2010, 33, 375-377.	8.6	105
207	Studies of association between LPIN1 variants and common metabolic phenotypes among 17 538 Danes. European Journal of Endocrinology, 2010, 163, 81-87.	3.7	16
208	Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans. Diabetes, 2010, 59, 2160-2163.	0.6	126
209	On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans. American Journal of Physiology - Endocrinology and Metabolism, 2010, 298, E614-E621.	3.5	64
210	Effect of Glucagon-Like Peptide-1 on α- and β-Cell Function in C-Peptide-Negative Type 1 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2492-2496.	3.6	45
211	Do the Actions of Glucagon-Like Peptide-1 on Gastric Emptying, Appetite, and Food Intake Involve Release of Amylin in Humans?. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2367-2375.	3.6	31
212	The insulin-resistant phenotype of polycystic ovary syndrome. Fertility and Sterility, 2010, 94, 1052-1058.	1.0	31
213	Pancreatic β-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes. Regulatory Peptides, 2010, 160, 175-180.	1.9	6
214	Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. Regulatory Peptides, 2010, 163, 96-101.	1.9	18
215	Relationship between common lipoprotein lipase gene sequence variants, hyperinsulinemia, and risk of ischemic heart disease: A population-based study. Atherosclerosis, 2010, 211, 506-511.	0.8	10
216	G-allele of Intronic rs10830963 in <i>MTNR1B</i> Confers Increased Risk of Impaired Fasting Glycemia and Type 2 Diabetes Through an Impaired Glucose-Stimulated Insulin Release. Diabetes, 2009, 58, 1450-1456.	0.6	125

#	Article	IF	CITATIONS
217	Incretin-Based Therapies. Diabetes Care, 2009, 32, S223-S231.	8.6	143
218	Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4679-4687.	3.6	89
219	Effect of Hyperglycemia on Mitochondrial Respiration in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1372-1378.	3.6	61
220	K _{ATP} Channel Closure Ameliorates the Impaired Insulinotropic Effect of Glucose-Dependent Insulinotropic Polypeptide in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 603-608.	3.6	48
221	Intramyocellular triglyceride content in man, influence of sex, obesity and glycaemic control. European Journal of Endocrinology, 2009, 161, 57-64.	3.7	13
222	Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 463-477.	4.7	108
223	Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Metabolism: Clinical and Experimental, 2009, 58, 586-593.	3.4	44
224	Reduced skeletal muscle mitochondrial respiration and improved glucose metabolism in nondiabetic obese women during a very low calorie dietary intervention leading to rapid weight loss. Metabolism: Clinical and Experimental, 2009, 58, 1145-1152.	3.4	63
225	Skeletal muscle structural lipids improve during weight-maintenance after a very low calorie dietary intervention. Lipids in Health and Disease, 2009, 8, 34.	3.0	10
226	Liraglutide Effect and Action in Diabetes (LEADâ,,¢) trial. Expert Review of Endocrinology and Metabolism, 2009, 4, 119-129.	2.4	50
227	Treatment of type 2 diabetes with incretin-based therapies. Lancet, The, 2009, 373, 438-439.	13.7	31
228	Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists. Current Diabetes Reviews, 2009, 5, 266-275.	1.3	49
229	GLPâ€1: physiological effects and potential therapeutic applications. Diabetes, Obesity and Metabolism, 2008, 10, 994-1003.	4.4	73
230	Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends in Molecular Medicine, 2008, 14, 161-168.	6.7	152
231	Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2008, 372, 1906-1913.	13.7	173
232	C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 594-598.	2.8	40
233	Obesity, body composition and metabolic disturbances in polycystic ovary syndrome. Human Reproduction, 2008, 23, 2113-2121.	0.9	80
234	Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Current Opinion in Clinical Nutrition and Metabolic Care, 2008, 11, 491-499.	2.5	85

#	Article	IF	CITATIONS
235	Altered PI3-Kinase/Akt Signalling in Skeletal Muscle of Young Men with Low Birth Weight. PLoS ONE, 2008, 3, e3738.	2.5	76
236	Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes. Diabetes Care, 2007, 30, 1608-1610.	8.6	415
237	Altered Skeletal Muscle Fiber Composition and Size Precede Whole-Body Insulin Resistance in Young Men with Low Birth Weight. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1530-1534.	3.6	122
238	Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E324-E330.	3.5	92
239	The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Regulatory Peptides, 2007, 144, 123-130.	1.9	55
240	Studies of association of the CASQ1 rs2275703 polymorphism in relation to type 2 diabetes and related quantitative metabolic traits among 7088 Danish whites. Molecular Genetics and Metabolism, 2007, 92, 278-282.	1.1	2
241	Reduced Incretin Effect in Type 2 Diabetes. Diabetes, 2007, 56, 1951-1959.	0.6	297
242	Insulin Resistance, the Metabolic Syndrome, and Risk of Incident Cardiovascular Disease. Journal of the American College of Cardiology, 2007, 49, 2112-2119.	2.8	225
243	Glucose production, oxidation and disposal correlate with plasma lactate levels in HIV-infected patients on HAART. Journal of Infection, 2007, 54, 89-97.	3.3	6
244	Desaturation of Skeletal Muscle Structural and Depot Lipids in Obese Individuals during a Very‣ow alorie Diet Intervention. Obesity, 2007, 15, 117-117.	3.0	20
245	Circulating sex hormones and gene expression of subcutaneous adipose tissue oestrogen and alpha-adrenergic receptors in HIV-lipodystrophy: implications for fat distribution. Clinical Endocrinology, 2007, 67, 250-258.	2.4	7
246	Insulin and New Insulin Analogues with Focus on Type 2 Diabetes. , 2007, , 53-65.		2
247	Tumor necrosis factor α is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. Metabolism: Clinical and Experimental, 2006, 55, 175-182.	3.4	38
248	The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regulatory Peptides, 2006, 137, 168-172.	1.9	52
249	Dietary intervention increases n-3 long-chain polyunsaturated fatty acids in skeletal muscle membrane phospholipids of obese subjects. Implications for insulin sensitivity. Clinical Endocrinology, 2006, 64, 169-178.	2.4	67
250	?-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Clinical Endocrinology, 2006, 65, 554-554.	2.4	0
251	Growth factors, glucose and insulin kinetics after low dose growth hormone therapy in HIV-lipodystrophy. Journal of Infection, 2006, 52, 389-398.	3.3	8
252	Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. European Journal of Endocrinology, 2006, 155, 485-493.	3.7	168

#	Article	IF	CITATIONS
253	IRS-1 Serine Phosphorylation and Insulin Resistance in Skeletal Muscle From Pancreas Transplant Recipients. Diabetes, 2006, 55, 785-791.	0.6	47
254	beta-Cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Clinical Endocrinology, 2005, 62, 354-361.	2.4	22
255	Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy. Journal of Medical Virology, 2005, 77, 29-38.	5.0	36
256	Genetic and Nongenetic Regulation of CAPN10 mRNA Expression in Skeletal Muscle. Diabetes, 2005, 54, 3015-3020.	0.6	30
257	Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic β-cells. European Journal of Endocrinology, 2005, 152, 103-112.	3.7	32
258	Normal Secretion and Action of the Gut Incretin Hormones Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Young Men with Low Birth Weight. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4912-4919.	3.6	31
259	Altered Fat Tissue Distribution in Young Adult Men Who Had Low Birth Weight. Diabetes Care, 2005, 28, 151-153.	8.6	81
260	Skeletal Muscle Insulin Signaling Defects Downstream of Phosphatidylinositol 3-Kinase at the Level of Akt Are Associated With Impaired Nonoxidative Glucose Disposal in HIV Lipodystrophy. Diabetes, 2005, 54, 3474-3483.	0.6	29
261	In nondiabetic, human immunodeficiency virus–infected patients with lipodystrophy, hepatic insulin extraction and posthepatic insulin clearance rate are decreased in proportion to insulin resistance. Metabolism: Clinical and Experimental, 2005, 54, 171-179.	3.4	8
262	Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor Î ³ coactivator 1α (PGC-1α) gene in Danish subjects with the metabolic syndrome. Diabetes Research and Clinical Practice, 2005, 67, 175-179.	2.8	38
263	Young, low-birth-weight men are not more susceptible to the diabetogenic effects of a prolonged free fatty acid exposure than matched controls. Metabolism: Clinical and Experimental, 2005, 54, 1398-1406.	3.4	3
264	Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of β-cells. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E677-E685.	3.5	23
265	Dissociation between Fat-Inducedin VivoInsulin Resistance and Proximal Insulin Signaling in Skeletal Muscle in Men at Risk for Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1301-1311.	3.6	52
266	Additive Effects of Glucagon-Like Peptide 1 and Pioglitazone in Patients With Type 2 Diabetes. Diabetes Care, 2004, 27, 1910-1914.	8.6	35
267	Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy. Scandinavian Journal of Infectious Diseases, 2004, 36, 832-839.	1.5	17
268	Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211). Diabetes Care, 2004, 27, 1335-1342.	8.6	296
269	Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2004, 351, 1952-1961.	27.0	844
270	Insulin-like growth factors, insulin-like growth factor-binding proteins, insulin-like growth factor-binding protein-3 protease, and growth hormone-binding protein in lipodystrophic Human Immunodeficiency Virus-infected patients. Metabolism: Clinical and Experimental, 2004, 53, 1565-1573.	3.4	12

#	Article	IF	CITATIONS
271	Insulin secretion after short- and long-term low-grade free fatty acid infusion in men with increased risk of developing type 2 diabetes. Metabolism: Clinical and Experimental, 2003, 52, 885-894.	3.4	55
272	Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in β-cell function. Metabolism: Clinical and Experimental, 2003, 52, 1343-1353.	3.4	48
273	Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regulatory Peptides, 2003, 114, 115-121.	1.9	360
274	The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion: Effects on Â-Cell Sensitivity in Type 2 and Nondiabetic Subjects. Diabetes, 2003, 52, 380-386.	0.6	513
275	Increased expression of TNF-α, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. American Journal of Physiology - Endocrinology and Metabolism, 2003, 285, E1072-E1080.	3.5	165
276	Insulin Secretion and Cellular Glucose Metabolism after Prolonged Low-Grade Intralipid Infusion in Young Men. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2775-2783.	3.6	39
277	No Hypoglycemia After Subcutaneous Administration of Glucagon-Like Peptide-1 in Lean Type 2 Diabetic Patients and in Patients With Diabetes Secondary to Chronic Pancreatitis. Diabetes Care, 2003, 26, 2581-2587.	8.6	39
278	Improved Postprandial Glycemic Control With Biphasic Insulin Aspart Relative to Biphasic Insulin Lispro and Biphasic Human Insulin in Patients With Type 2 Diabetes. Diabetes Care, 2002, 25, 883-888.	8.6	125
279	Studies of the Pro12Ala Polymorphism of the PPAR-Î ³ Gene in the Danish MONICA Cohort: Homozygosity of the Ala Allele Confers a Decreased Risk of the Insulin Resistance Syndrome. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3989-3992.	3.6	112
280	Early Differential Defects of Insulin Secretion and Action in 19-Year-Old Caucasian Men Who Had Low Birth Weight. Diabetes, 2002, 51, 1271-1280.	0.6	172
281	Sulfatide Controls Insulin Secretion by Modulation of ATP-sensitive K+-Channel Activity and Ca2+-Dependent Exocytosis in Rat Pancreatic Â-Cells. Diabetes, 2002, 51, 2514-2521.	0.6	46
282	Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet, The, 2002, 359, 824-830.	13.7	1,207
283	Determinants of the Impaired Secretion of Clucagon-Like Peptide-1 in Type 2 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3717-3723.	3.6	767
284	Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3717-3723.	3.6	224
285	Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives. Contraception, 1999, 60, 337-344.	1.5	23
286	Insulin secretion rates estimated by two mathematical methods in pancreas-kidney transplant recipients. American Journal of Physiology - Endocrinology and Metabolism, 1998, 274, E716-E725.	3.5	9
287	Sham Feeding Increases Glucose Tolerance by a Mechanism Independent of Insulin Secretion in Normal Subjects. Digestion, 1995, 56, 253-258.	2.3	9
288	Clinical evaluation of a prototype glucose electrode. Biosensors and Bioelectronics, 1992, 7, 683-687.	10.1	2

#	Article	IF	CITATIONS
289	A rapid method for determination of human C-peptide in plasma. Clinica Chimica Acta, 1991, 196, 1-6.	1.1	2
290	Gastric Inhibitory Polypeptide in Newly Diagnosed Ketotic Type I (Insulinâ€dependent) Diabetics. Acta Medica Scandinavica, 1988, 223, 437-441.	0.0	7
291	Metabolic and Cardiovascular Responses to Epinephrine in Diabetic Autonomic Neuropathy. New England Journal of Medicine, 1987, 317, 421-426.	27.0	66
292	Heterogeneity of immunoreactive gastric inhibitory polypeptide in the plasma of newly diagnosed type 1 (insulin-dependent) diabetics. European Journal of Endocrinology, 1987, 114, 74-83.	3.7	6
293	Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus. Metabolism: Clinical and Experimental, 1987, 36, 677-682.	3.4	107
294	Rapid changes in plasma androgens during insulin withdrawal in male Type 1 (insulin-dependent) diabetics. Journal of Endocrinological Investigation, 1986, 9, 21-25.	3.3	6
295	The importance of plasma free insulin and counterregulatory hormones for the recovery of blood glucose following hypoglycaemia in Type 1 diabetics. European Journal of Endocrinology, 1985, 108, 224-230.	3.7	14
296	Relation of immunoreactive gastric inhibitory polypeptide to changes in glycaemic control and B cell function in Type 1 (insulin-dependent) diabetes mellitus. European Journal of Endocrinology, 1984, 105, 221-225.	3.7	5
297	Factors of Importance for Residual Betaâ€cell Function in Type I Diabetes Mellitus. Acta Medica Scandinavica, 1983, 213, 61-67.	0.0	8
298	Whole Body Clearance of Norepinephrine. THE SIGNIFICANCE OF ARTERIAL SAMPLING AND OF SURGICAL STRESS. Journal of Clinical Investigation, 1983, 71, 500-505.	8.2	61
299	Plasma testosterone and androstenedione in insulin dependent patients at time of diagnosis and during the first year of insulin treatment. European Journal of Endocrinology, 1982, 100, 406-409.	3.7	23
300	No Response of Pancreatic Hormones to Hypoglycemia in Diabetic Autonomic Neuropathy*. Journal of Clinical Endocrinology and Metabolism, 1982, 54, 815-819.	3.6	49
301	Hyponatremia and hyperkalemia in relation to hyperglycemia in insulin-treated diabetic out-patients. Clinica Chimica Acta, 1982, 120, 243-250.	1.1	36
302	Renal hypomagnesaemia in human diabetes mellitus: its relation to glucose homeostasis. European Journal of Clinical Investigation, 1982, 12, 81-85.	3.4	167
303	Decreased Insulin Removal Contributes to Hyperinsulinemia in Obesity. Journal of Clinical Endocrinology and Metabolism, 1981, 53, 618-621.	3.6	170
304	Practical Clinical Value of the Câ€Peptide Response to Glucagon Stimulation in the Choice of Treatment in Diabetes Mellitus. Acta Medica Scandinavica, 1981, 210, 153-156.	0.0	154
305	Insulin secretory reserve in insulin dependent patients at time of diagnosis and the first 180 days of insulin treatment. European Journal of Endocrinology, 1980, 95, 359-363.	3.7	43